Share ownership AnteoTech Limited

ADO

AU000000ADO8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:59:28 2026-04-17 am EDT			5-day change	1st Jan Change
0.0110 ^AUD	-8.33%		-8.33%	-50.00%

Mar. 01	AnteoTech Limited, H1 2026 Earnings Call, Mar 02, 2026
Feb. 24	AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI

Share class: AnteoTech Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,738,747,015	2,482,930,644 ( 90.66 %)	0	90.66 %

Major shareholders: AnteoTech Limited

Name	Equities	%	Valuation
Levenson Investments Pty Ltd. 2.102 %	62,500,000	2.102 %	513 750 $
First Cape Management Pty Ltd. 1.856 %	55,195,509	1.856 %	453 707 $
Addison Lake Quality Hire Pty Ltd. 1.307 %	38,844,879	1.307 %	319 305 $
Fossil Super Pty Ltd. 1.012 %	30,100,000	1.012 %	247 422 $
Peter Frederick Kemmis 0.9112 %	27,090,676	0.9112 %	222 685 $
Anthony William Olding 0.828 %	24,617,142	0.828 %	202 353 $
Awo & Cao Investments Pty Ltd. 0.7753 %	23,050,000	0.7753 %	189 471 $
Computer Visions Pty Ltd. 0.7444 %	22,132,994	0.7444 %	181 933 $
Mcrae Superannuation Pty Ltd. 0.7442 %	22,125,000	0.7442 %	181 868 $
Mary Curtis 0.6598 %	19,617,450	0.6598 %	161 255 $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Other	9.16%
Individuals	4.3%
Unknown	86.54%

Based on 1000 largest holdings

Geographical origin of shareholders

Australia	9.16%
Individuals	4.3%

Based on 1000 largest holdings

AnteoTech Limited is an Australia-based company engaged in providing solutions for the clean energy and life sciences markets using applied materials technology. The principal activities of the Company consist of development and commercialization of nanotechnologies with surface management applications. The Companyâ€™s lead product, Anteo X, provides significant improvement in anode performance and the Company partners with global suppliers in lithium-ion battery manufacturing. Its clean energy technology (CET) technologies improve the energy densities, cycle life and cost- effectiveness of lithium-ion batteries. The Company has two programs underway: Anteo X, its binder additive and the High Silicon Anode technology. The Life Sciences division services the point-of-care and in vitro diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

Employees

Sector

Biotechnology & Medical Research

More about the company